Bayer Pharma AG / Xarelto®
Xarelto® is approved for the prevention of stroke in atrial fibrillation and for the treatment and prevention of deep vein thrombosis. Xarelto® belongs to the new class of drugs called “direct oral anticoagulants” or DOAKs. Xarelto® is characterized by a particularly simple dosage (e.g. compared to the dosage of vitamin K antagonists) and is administered by taking tablets once a day.
Development and implementation of global marketing materials for the digital channels: eDetailer, eLearning applications, ePanels, including ad hoc services during the congress phases